Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Multiple Ascending Doses of AZD4041 in Healthy Adults
NCT05233085Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AZD4041 in opioid use disorder (OUD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Treatment-emergent Adverse Events, Abnormal Vital Signs Reported as TEAEs and 5 more. Started Dec 2021; status: completed.
02
Drugs
AZD4041
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05233085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233085.